{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T19:05:26Z","timestamp":1773860726499,"version":"3.50.1"},"reference-count":118,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SCHN 664\/3-2"],"award-info":[{"award-number":["SCHN 664\/3-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC1123 B07"],"award-info":[{"award-number":["CRC1123 B07"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008848","name":"Elite Network of Bavaria","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008848","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2012_A27"],"award-info":[{"award-number":["2012_A27"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.canlet.2016.02.057","type":"journal-article","created":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T07:16:25Z","timestamp":1457421385000},"page":"259-268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer"],"prefix":"10.1016","volume":"381","author":[{"given":"Christian","family":"Bauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"K\u00fchnemuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0836-6448","authenticated-orcid":false,"given":"Peter","family":"Duewell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Ormanns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Gress","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Schnurr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2016.02.057_bib0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J. Clin"},{"key":"10.1016\/j.canlet.2016.02.057_bib0015","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3322\/caac.21190","article-title":"Recent progress in pancreatic cancer","volume":"63","author":"Wolfgang","year":"2013","journal-title":"CA Cancer J. Clin"},{"key":"10.1016\/j.canlet.2016.02.057_bib0020","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0025","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/oxfordjournals.annonc.a010600","article-title":"A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer","volume":"7","author":"Rothenberg","year":"1996","journal-title":"Ann. Oncol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0030","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","article-title":"Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial","volume":"29","author":"Von Hoff","year":"2011","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0035","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.canlet.2016.02.057_bib0040","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1158\/1078-0432.CCR-14-1269","article-title":"Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma","volume":"20","author":"Kim","year":"2014","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2016.02.057_bib0045","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","article-title":"Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma","volume":"25","author":"Rhim","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2016.02.057_bib0050","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2016.02.057_bib0055","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2016.02.057_bib0060","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/CJI.0b013e31829fb7a2","article-title":"Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer","volume":"36","author":"Le","year":"2013","journal-title":"J. Immunother"},{"key":"10.1016\/j.canlet.2016.02.057_bib0065","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J. Immunother"},{"key":"10.1016\/j.canlet.2016.02.057_bib0070","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2016.02.057_bib0075","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1158\/2326-6066.CIR-14-0215","article-title":"Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma","volume":"3","author":"Winograd","year":"2015","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.canlet.2016.02.057_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000062","article-title":"PD-1\/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors","volume":"38","author":"Soares","year":"2015","journal-title":"J. Immunother"},{"key":"10.1016\/j.canlet.2016.02.057_bib0085","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/00006676-200401000-00023","article-title":"CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma","volume":"28","author":"Fukunaga","year":"2004","journal-title":"Pancreas"},{"key":"10.1016\/j.canlet.2016.02.057_bib0090","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1053\/j.gastro.2013.07.025","article-title":"Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma","volume":"145","author":"Ene-Obong","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2016.02.057_bib0095","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10585-008-9196-9","article-title":"Intravital imaging of CD8+ T cell function in cancer","volume":"26","author":"Mempel","year":"2009","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.canlet.2016.02.057_bib0100","doi-asserted-by":"crossref","first-page":"9518","DOI":"10.1158\/0008-5472.CAN-07-0175","article-title":"Dynamics of the immune reaction to pancreatic cancer from inception to invasion","volume":"67","author":"Clark","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2016.02.057_bib0105","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000007488","article-title":"Immunohistochemical characterization of the pancreatic cellular infiltrate in normal pancreas, chronic pancreatitis and pancreatic carcinoma","volume":"59","author":"Emmrich","year":"1998","journal-title":"Digestion"},{"key":"10.1016\/j.canlet.2016.02.057_bib0110","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00262-014-1529-8","article-title":"P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma","volume":"63","author":"Terashima","year":"2014","journal-title":"Cancer Immunol. Immunother"},{"key":"10.1016\/j.canlet.2016.02.057_bib0115","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/bjc.2013.32","article-title":"Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer","volume":"108","author":"Ino","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2016.02.057_bib0120","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00262-013-1427-5","article-title":"CD40 immunotherapy for pancreatic cancer","volume":"62","author":"Vonderheide","year":"2013","journal-title":"Cancer Immunol. Immunother"},{"key":"10.1016\/j.canlet.2016.02.057_bib0125","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1172\/JCI66375","article-title":"Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction","volume":"124","author":"Bauer","year":"2014","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.canlet.2016.02.057_bib0130","doi-asserted-by":"crossref","first-page":"e96565","DOI":"10.1371\/journal.pone.0096565","article-title":"Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment","volume":"9","author":"Shibuya","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.canlet.2016.02.057_bib0135","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00432-008-0364-8","article-title":"B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression","volume":"134","author":"Geng","year":"2008","journal-title":"J. Cancer Res. Clin. Oncol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0140","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jamcollsurg.2007.12.014","article-title":"Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection","volume":"206","author":"Witkiewicz","year":"2008","journal-title":"J. Am. Coll. Surg"},{"key":"10.1016\/j.canlet.2016.02.057_bib0145","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/carcin\/bgu115","article-title":"Stromal reengineering to treat pancreas cancer","volume":"35","author":"Stromnes","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2016.02.057_bib0150","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1136\/gutjnl-2015-309304","article-title":"Stromal biology and therapy in pancreatic cancer: a changing paradigm","volume":"64","author":"Neesse","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.canlet.2016.02.057_bib0155","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jss.2010.09.027","article-title":"Circulating myeloid dendritic cells as prognostic factors in patients with pancreatic cancer who have undergone surgical resection","volume":"173","author":"Yamamoto","year":"2012","journal-title":"J. Surg. Res"},{"key":"10.1016\/j.canlet.2016.02.057_bib0160","doi-asserted-by":"crossref","first-page":"e13441","DOI":"10.1371\/journal.pone.0013441","article-title":"Semi mature blood dendritic cells exist in patients with ductal pancreatic adenocarcinoma owing to inflammatory factors released from the tumor","volume":"5","author":"Tjomsland","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.canlet.2016.02.057_bib0165","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.gastro.2015.04.010","article-title":"Exclusion of T cells from pancreatic carcinomas in mice is regulated by Ly6C(low) F4\/80(+) extratumoral macrophages","volume":"149","author":"Beatty","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2016.02.057_bib0170","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"Ozdemir","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2016.02.057_bib0175","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2016.02.057_bib0180","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1084\/jem.20122344","article-title":"Depletion of stromal cells expressing fibroblast activation protein-alpha from skeletal muscle and bone marrow results in cachexia and anemia","volume":"210","author":"Roberts","year":"2013","journal-title":"J. Exp. Med"},{"issue":"4","key":"10.1016\/j.canlet.2016.02.057_bib0185","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00262-013-1510-y","article-title":"Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8 T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model","volume":"63","author":"Bauer","year":"2014","journal-title":"Cancer Immunol. Immunother"},{"key":"10.1016\/j.canlet.2016.02.057_bib0190","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1158\/0008-5472.CAN-11-3850","article-title":"Therapeutic efficacy of bifunctional siRNA combining TGF-beta1 silencing with RIG-I activation in pancreatic cancer","volume":"73","author":"Ellermeier","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2016.02.057_bib0195","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/cdd.2014.96","article-title":"RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells","volume":"21","author":"Duewell","year":"2014","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.canlet.2016.02.057_bib0200","doi-asserted-by":"crossref","first-page":"e955687","DOI":"10.4161\/21624011.2014.955687","article-title":"Induction of immunogenic cell death by targeting RIG-I-like helicases in pancreatic cancer","volume":"3","author":"Schnurr","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2016.02.057_bib0205","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2016.02.057_bib0210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2051-1426-2-3","article-title":"Mechanism of tumor rejection with doublets of CTLA-4, PD-1\/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment","volume":"2","author":"Spranger","year":"2014","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2016.02.057_bib0215","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0220","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2016.02.057_bib0225","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/eji.201142275","article-title":"Antigen amount dictates CD8+ T-cell exhaustion during chronic viral infection irrespective of the type of antigen presenting cell","volume":"42","author":"Richter","year":"2012","journal-title":"Eur. J. Immunol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0230","doi-asserted-by":"crossref","first-page":"8623","DOI":"10.1073\/pnas.0809818106","article-title":"High antigen levels are the cause of T cell exhaustion during chronic viral infection","volume":"106","author":"Mueller","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2016.02.057_bib0235","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1128\/JVI.77.8.4911-4927.2003","article-title":"Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment","volume":"77","author":"Wherry","year":"2003","journal-title":"J. Virol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0240","doi-asserted-by":"crossref","first-page":"8161","DOI":"10.1128\/JVI.00889-12","article-title":"Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection","volume":"86","author":"Angelosanto","year":"2012","journal-title":"J. Virol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0245","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","article-title":"The transcription factor NFAT promotes exhaustion of activated CD8(+) T cells","volume":"42","author":"Martinez","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2016.02.057_bib0250","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.4049\/jimmunol.181.7.4832","article-title":"NFATc1 regulates PD-1 expression upon T cell activation","volume":"181","author":"Oestreich","year":"2008","journal-title":"J. Immunol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0255","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/ni.2771","article-title":"Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency","volume":"15","author":"Lucas","year":"2014","journal-title":"Nat. Immunol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0260","doi-asserted-by":"crossref","first-page":"1242454","DOI":"10.1126\/science.1242454","article-title":"Fueling immunity: insights into metabolism and lymphocyte function","volume":"342","author":"Pearce","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.canlet.2016.02.057_bib0265","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nri3485","article-title":"Immunometabolism: what is the point of Warburg?","volume":"13","author":"Minton","year":"2013","journal-title":"Nat. Rev. Immunol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0270","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.cell.2013.05.016","article-title":"Posttranscriptional control of T cell effector function by aerobic glycolysis","volume":"153","author":"Chang","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2016.02.057_bib0275","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4049\/jimmunol.0902373","article-title":"Early CD4(+) T cell help prevents partial CD8(+) T cell exhaustion and promotes maintenance of Herpes Simplex Virus 1 latency","volume":"184","author":"Frank","year":"2010","journal-title":"J. Immunol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0280","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm1492","article-title":"Interleukin-10 determines viral clearance or persistence in vivo","volume":"12","author":"Brooks","year":"2006","journal-title":"Nat. Med"},{"key":"10.1016\/j.canlet.2016.02.057_bib0285","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.immuni.2009.06.015","article-title":"Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo","volume":"31","author":"Tinoco","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2016.02.057_bib0290","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.1235214","article-title":"Persistent LCMV infection is controlled by blockade of type I interferon signaling","volume":"340","author":"Teijaro","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.canlet.2016.02.057_bib0295","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1126\/science.1235208","article-title":"Blockade of chronic type I interferon signaling to control persistent LCMV infection","volume":"340","author":"Wilson","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.canlet.2016.02.057_bib0300","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat. Rev. Immunol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0305","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1084\/jem.188.12.2205","article-title":"Viral immune evasion due to persistence of activated T cells without effector function","volume":"188","author":"Zajac","year":"1998","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.canlet.2016.02.057_bib0310","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1084\/jem.187.9.1383","article-title":"Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes","volume":"187","author":"Gallimore","year":"1998","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.canlet.2016.02.057_bib0315","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.canlet.2016.02.057_bib0320","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2016.02.057_bib0325","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2016.02.057_bib0330","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2016.02.057_bib0335","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.it.2013.10.001","article-title":"Tolerance and exhaustion: defining mechanisms of T cell dysfunction","volume":"35","author":"Schietinger","year":"2014","journal-title":"Trends Immunol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0340","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends Immunol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0345","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1128\/JVI.01579-09","article-title":"Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion","volume":"84","author":"Blackburn","year":"2010","journal-title":"J. Virol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0350","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/ni.1790","article-title":"Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal","volume":"10","author":"Fife","year":"2009","journal-title":"Nat. Immunol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0355","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.immuni.2013.11.017","article-title":"Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues","volume":"40","author":"Honda","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2016.02.057_bib0360","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1084\/jem.20121416","article-title":"PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis","volume":"210","author":"Zinselmeyer","year":"2013","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.canlet.2016.02.057_bib0365","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.canlet.2008.03.056","article-title":"Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer","volume":"268","author":"Loos","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1016\/j.canlet.2016.02.057_bib0370","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.4049\/jimmunol.1400557","article-title":"Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion","volume":"193","author":"Ferris","year":"2014","journal-title":"J. Immunol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0375","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1128\/MCB.05297-11","article-title":"Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways","volume":"31","author":"Lee","year":"2011","journal-title":"Mol. Cell. Biol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0380","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.canlet.2016.02.057_bib0385","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/dna.2011.1417","article-title":"Cytotoxic T-lymphocyte antigen-4 +49G\/A polymorphism and susceptibility to pancreatic cancer","volume":"31","author":"Lang","year":"2012","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0390","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1084\/jem.190.3.355","volume":"190","author":"van Elsas","year":"1999","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.canlet.2016.02.057_bib0395","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0400","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2014.58.1041","article-title":"Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab","volume":"33","author":"McDermott","year":"2015","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0405","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0410","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","article-title":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","volume":"21","author":"Ohaegbulam","year":"2015","journal-title":"Trends Mol. Med"},{"key":"10.1016\/j.canlet.2016.02.057_bib0415","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","article-title":"Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer","volume":"13","author":"Nomi","year":"2007","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2016.02.057_bib0420","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00268-010-0448-x","article-title":"Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma","volume":"34","author":"Wang","year":"2010","journal-title":"World J. Surg"},{"key":"10.1016\/j.canlet.2016.02.057_bib0425","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2016.02.057_bib0430","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2016.02.057_bib0435","doi-asserted-by":"crossref","first-page":"e27614","DOI":"10.4161\/onci.27614","article-title":"Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo","volume":"3","author":"Sandin","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2016.02.057_bib0440","first-page":"741","article-title":"Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model","volume":"35","author":"Okudaira","year":"2009","journal-title":"Int. J. Oncol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0445","doi-asserted-by":"crossref","first-page":"e1008814","DOI":"10.1080\/2162402X.2015.1008814","article-title":"Trial Watch: immunomodulatory monoclonal antibodies for oncological indications","volume":"4","author":"Buque","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2016.02.057_bib0450","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrc3565","article-title":"Gene-engineered T cells for cancer therapy","volume":"13","author":"Kershaw","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2016.02.057_bib0455","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.4049\/jimmunol.165.6.3451","article-title":"Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred","volume":"165","author":"Mukherjee","year":"2000","journal-title":"J. Immunol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0460","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00262-002-0277-3","article-title":"Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines","volume":"51","author":"Sivinski","year":"2002","journal-title":"Cancer Immunol. Immunother"},{"key":"10.1016\/j.canlet.2016.02.057_bib0465","first-page":"3709","article-title":"Efficacy of immuno-cell therapy in patients with advanced pancreatic cancer","volume":"25","author":"Kaneko","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.canlet.2016.02.057_bib0470","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/hum.2013.209","article-title":"A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer","volume":"25","author":"Abate-Daga","year":"2014","journal-title":"Hum. Gene Ther"},{"key":"10.1016\/j.canlet.2016.02.057_bib0475","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1053\/j.gastro.2012.06.037","article-title":"T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice","volume":"143","author":"Chmielewski","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2016.02.057_bib0480","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv146","article-title":"Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy","volume":"107","author":"Kobold","year":"2015","journal-title":"J. Natl Cancer Inst"},{"key":"10.1016\/j.canlet.2016.02.057_bib0485","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.canlet.2016.02.057_bib0490","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jlb.67.1.2","article-title":"CD40-CD40 ligand","volume":"67","author":"van Kooten","year":"2000","journal-title":"J. Leukoc. Biol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0495","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/30845","article-title":"Immunology. Licence to kill","volume":"393","author":"Lanzavecchia","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2016.02.057_bib0500","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.immunol.22.012703.104533","article-title":"CD40\/CD154 interactions at the interface of tolerance and immunity","volume":"22","author":"Quezada","year":"2004","journal-title":"Annu. Rev. Immunol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0505","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.canlet.2016.02.057_bib0510","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1158\/1078-0432.CCR-13-1320","article-title":"A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma","volume":"19","author":"Beatty","year":"2013","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2016.02.057_bib0515","doi-asserted-by":"crossref","first-page":"e23033","DOI":"10.4161\/onci.23033","article-title":"Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors","volume":"2","author":"Vonderheide","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2016.02.057_bib0520","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00262-011-1023-5","article-title":"Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study","volume":"60","author":"Bauer","year":"2011","journal-title":"Cancer Immunol. Immunother"},{"key":"10.1016\/j.canlet.2016.02.057_bib0525","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1479-5876-12-175","article-title":"Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer","volume":"12","author":"Shindo","year":"2014","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.canlet.2016.02.057_bib0530","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/ijc.25399","article-title":"An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma","volume":"128","author":"Jacobs","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2016.02.057_bib0535","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4049\/jimmunol.1004114","article-title":"ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells","volume":"187","author":"Duewell","year":"2011","journal-title":"J. Immunol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0540","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00262-004-0638-1","article-title":"Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas","volume":"54","author":"Plate","year":"2005","journal-title":"Cancer Immunol. Immunother"},{"key":"10.1016\/j.canlet.2016.02.057_bib0545","first-page":"2353","article-title":"Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy","volume":"62","author":"Nowak","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2016.02.057_bib0550","first-page":"4490","article-title":"Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors","volume":"63","author":"Nowak","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2016.02.057_bib0555","first-page":"187","article-title":"Combinatorial strategies for the induction of immunogenic cell death","volume":"6","author":"Bezu","year":"2015","journal-title":"Front. Immunol"},{"key":"10.1016\/j.canlet.2016.02.057_bib0560","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MPA.0b013e3182575e4a","article-title":"Indoleamine 2,3-dioxygenase affects the aggressiveness of intraductal papillary mucinous neoplasms through Foxp3+CD4+CD25+ T cells in peripheral blood","volume":"42","author":"Ikemoto","year":"2013","journal-title":"Pancreas"},{"key":"10.1016\/j.canlet.2016.02.057_bib0565","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1186\/1471-2407-14-738","article-title":"Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction","volume":"14","author":"Peng","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2016.02.057_bib0570","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1158\/2326-6066.CIR-14-0214","article-title":"Salmonella-based therapy targeting indoleamine 2,3-dioxygenase coupled with enzymatic depletion of tumor hyaluronan induces complete regression of aggressive pancreatic tumors","volume":"3","author":"Manuel","year":"2015","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.canlet.2016.02.057_bib0575","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.molmed.2015.05.005","article-title":"Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system","volume":"21","author":"Pico de Coana","year":"2015","journal-title":"Trends Mol. Med"},{"key":"10.1016\/j.canlet.2016.02.057_bib0580","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2326-6066.CIR-14-0027","article-title":"Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation","volume":"2","author":"Lutz","year":"2014","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.canlet.2016.02.057_bib0585","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2016.02.057_bib0590","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2016.02.057_bib0595","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semradonc.2014.07.004","article-title":"Combination of radiotherapy and immune checkpoint inhibitors","volume":"25","author":"Pilones","year":"2015","journal-title":"Semin. Radiat. Oncol"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516301355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516301355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T18:18:16Z","timestamp":1656353896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383516301355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":118,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0304383516301355"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2016.02.057","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2016.02.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}